Trang 1 từ 170 các kết quả
Description of five characteristic cases of macular edema caused by senile posterior vitreous detachment. Fluorescein angiography revealed no abnormalities and the macula remained devoid of significant changes. In cases where a fluorescein leakage in the macular area was found, a thick preretinal
OBJECTIVE
To evaluate the effects of posterior vitreous detachment (PVD) in macular edema associated with central retinal vein occlusion (CRVO) treated with intravitreal tissue plasminogen activator (tPA).
METHODS
The authors conducted a retrospective study of 36 eyes of 36 patients with macular
OBJECTIVE
To establish the influence of posterior vitreous detachment on development and resolution of diabetic macular edema in NIDDM. To asses the posterior vitreous detachment role in argon laser treatment of diabetic macular edema.
METHODS
Retrospective study.
RESULTS
68 eyes of 36 patients were
The purpose of this study was to determine the morphological and functional changes in the macula after pars plana vitrectomy with the creation of a posterior vitreous detachment in eyes with diabetic macular edema (DME). A simple posterior vitreous detachment was created during pars plana
To determine if vitreous changes play a role in macular edema, 197 eyes were selected, 113 with macular edema (68 diffuse and 45 cystoid) associated with different pathologies. We studied the vitreoretinal relationship in all cases. Photocoagulation was done in 21 eyes and vitreous examination
OBJECTIVE
To assess preoperative factors associated with postoperative posterior vitreous detachment (PVD) following intravitreal autologous plasmin injection in diabetic macular edema associated with vitreomacular traction.
METHODS
Twenty-five eyes with diabetic macular edema associated with
OBJECTIVE
To assess the effectiveness of surgical posterior vitreous detachment (PVD) together with gas/air tamponade in treating visual impairment from macular edema associated with branch retinal vein occlusion (BRVO-macular edema).
METHODS
A cohort study was conducted. To treat visual disturbance
OBJECTIVE
To investigate whether angiotensin II (AII) or vascular endothelial growth factor (VEGF) is related to diabetic macular edema (DME) in patients with and without posterior vitreous detachment (PVD).
METHODS
A case-control study.
METHODS
Vitreous fluid samples were obtained at vitreoretinal
PURPOSE. To present the vitreoretinal interface in diabetic macular edema (DME) associated with both epiretinal membrane (ERM) and incomplete posterior vitreous detachment (PVD), as detected by spectral-domain optical coherence tomography (SD-OCT). METHODS. In a retrospective study, findings were
OBJECTIVE
To evaluate the effects of intravitreal injection of recombinant tissue plasminogen activator (TPA) for the treatment of refractory diabetic macular edema.
METHODS
A total of 27 patients with refractory diabetic macular edema with no evidence of posterior vitreous detachment were randomly
To evaluate the vitreomacular interface and its relation to treatment burden for diabetic macular edema (DME) in patients without overt vitreomacular traction (VMT).A retrospective cohort study of 494 eyes from 274 patients who had macular spectral-domain OBJECTIVE
To evaluate the surgical efficacy of pars plana vitrectomy on eyes with diabetic macular edema in the presence or absence of a complete posterior vitreous detachment and with or without an epimacular membrane.
METHODS
Pars plana vitrectomy was performed on 30 eyes of 29 cases with diabetic
We report three cases of persistent vitreous hemorrhage after injection of a biodegradable 0.7 mg dexamethasone intravitreal implant (Ozurdex, Allergan), (DEX) to treat and manage diabetic macular edema (DME); we also summarize available case reports and review the literature regarding persistent